TABLE 1.
Clinical data of the CSF and blood serum study cohort for three studied groups –AD and MCI diagnosed patients, and Con samples from hospital patients with various comorbidities that are not affecting poor CSF biomarker scores.
| Total | Con | MCI | AD | |
| CSF cohort | ||||
| Patients | 71 | 20 | 22 | 29 |
| Male | 43 | 13 | 16 | 14 |
| Female | 28 | 7 | 6 | 15 |
| Age (mean ± SD) | 68.0 ± 8.2 | 69.7 ± 7.0 | 69.5 ± 9.8 | 65.6 ± 7.3* |
| MMSE (mean ± SD) | 27.0 ± 1.9 | 22.5 ± 3.6 *** | ||
| Blood serum cohort | ||||
| Patients | 76 | 29 | 21 | 26 |
| Male | 38 | 15 | 15 | 13 |
| Female | 33 | 14 | 6 | 13 |
| Age (mean ± SD) | 69.0 ± 7.7 | 71.7 ± 4.6 | 69.3 ± 10.0 | 65.9 ± 7.5*** |
| MMSE (mean ± SD) | 26.4 ± 3.4 | 29.2 ± 0.9 | 26.9 ± 1.9*** | 22.8 ± 3.4*** |
Herein, the MMSE scores have been added according to the available entries from the patient groups. Statistical significance (in comparisons with the Con group, while CSF MMSE scores were compared between AD and MCI groups): *P ≤ 0.05, ***P ≤ 0.001; SD, standard deviation.